Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881180 | 0.89 | HTR4 (0.51) | HTR4ALDH1A1PTK2HTR3AKDM4E | |
| SCHEMBL13461317 | 0.88 | HTR4 (0.52) | HTR4ALDH1A1PTK2HTR3AKDM4E | |
| SCHEMBL13575489 | 0.86 | HTR4 (0.49) | HTR4ALDH1A1PTK2KDM4EMEN1 | |
| SCHEMBL13881171 | 0.86 | MAPK1 (0.61) | HTR4ALDH1A1HTR3ADRD4 | |
| SCHEMBL13575564 | 0.85 | HTR4 (0.52) | HTR4CCNA2CDK2 | |
| SCHEMBL1163804 | 0.85 | KDM4E (0.51) | HTR4ALDH1A1PTK2KDM4EMEN1 | |
| SCHEMBL3535920 | 0.84 | HTR4 (0.47) | HTR4ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL14221621 | 0.84 | HTR4 (0.47) | HTR4ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL3539061 | 0.82 | KDM4E (0.69) | HTR4HTR3AKDM4EMEN1MAPT | |
| SCHEMBL3942580 | 0.81 | HTR4 (0.47) | HTR4KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | HTR4 4802/4885ALDH1A1 4009/4885PTK2 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.